Xilio Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	137.53	55.29	44.7	120.39	198.05
Cash & Short-Term Investments	137.53	55.29	44.7	120.39	198.05
Cash Growth	148.74%	23.68%	-62.87%	-39.22%	929.49%
Other Current Assets	7.5	4.94	3.42	4.11	4.46
Total Current Assets	145.03	60.23	48.13	124.5	202.52
Net Property, Plant & Equipment	7.85	9.06	11.07	12.84	13.6
Other Long-Term Assets	1.81	1.78	1.73	1.83	1.95
Total Assets	154.69	71.08	60.93	139.17	218.06
Accounts Payable	3.17	2.57	1.05	3.13	3.14
Accrued Expenses	11.74	9.98	10.5	10.33	8.75
Current Portion of Long-Term Debt	-	-	3.32	6.67	0.08
Current Portion of Leases	1.34	1.19	1.05	0.92	0.8
Unearned Revenue	40.02	13.52	-	-	-
Other Current Liabilities	-	-	0.05	0.08	12.78
Total Current Liabilities	56.27	27.26	15.96	21.12	12.78
Long-Term Debt	-	-	-	3.17	9.63
Long-Term Leases	5.61	6.95	8.14	9.19	10.11
Other Long-Term Liabilities	57.53	19.26	-	0.05	0.12
Total Long-Term Liabilities	63.14	26.22	8.14	12.4	19.85
Total Liabilities	119.41	53.48	24.1	33.52	32.63
Common Stock	-	-	0	0	0
Additional Paid-in Capital	454.06	401.35	362.34	354.75	346.31
Retained Earnings	-418.79	-383.75	-325.51	-249.11	-160.89
Total Common Shareholders' Equity	35.27	17.6	36.83	105.65	185.43
Shareholders' Equity	35.27	17.6	36.83	105.65	185.43
Total Liabilities & Equity	154.69	71.08	60.93	139.17	218.06
Total Debt	6.95	8.14	12.5	19.94	20.62
Net Cash (Debt)	130.58	47.15	32.2	100.45	177.44
Net Cash Growth	176.94%	46.42%	-67.94%	-43.39%	-
Net Cash Per Share	15.62	12.34	16.39	51.34	443.09
Book Value	35.27	17.6	36.83	105.65	185.43
Book Value Per Share	4.22	4.60	18.75	54.00	463.05
Tangible Book Value	35.27	17.6	36.83	105.65	185.43
Tangible Book Value Per Share	4.22	4.60	18.75	54.00	463.05

Updated Mar 23, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q